$1.44 Billion is the total value of Perceptive Advisors's 172 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 175.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SRPT | New | Sarepta Therapeutics Incput | $145,300,000 | – | 7,619,300 | +100.0% | 10.07% | – |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $127,167,000 | +18.2% | 2,797,967 | +2.8% | 8.82% | -6.6% |
| TSRO | Buy | TESARO INC | $96,121,000 | +98.7% | 1,143,615 | +4.1% | 6.66% | +57.1% |
| RTRX | Buy | Retrophin Inc | $58,405,000 | +42.6% | 3,279,380 | +9.3% | 4.05% | +12.7% |
| MDVN | Buy | MEDIVATION INC | $45,828,000 | +193.1% | 760,000 | +123.5% | 3.18% | +131.7% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $36,625,000 | +78.0% | 2,207,668 | +70.2% | 2.54% | +40.7% |
| NXTM | New | NXSTAGE MEDICAL INC | $29,971,000 | – | 1,382,410 | +100.0% | 2.08% | – |
| LBIO | Buy | LION BIOTECHNOLOGIES INC | $29,257,000 | +106.6% | 3,611,976 | +29.6% | 2.03% | +63.3% |
| XBI | New | STREETTRACKS SPDR BIOTEC ETFput | $27,045,000 | – | 500,000 | +100.0% | 1.88% | – |
| NVRO | Buy | NEVRO CORP | $26,939,000 | +37.4% | 365,229 | +4.8% | 1.87% | +8.6% |
| LJPC | Buy | LA JOLLA PHARMACEUTICAL CO | $21,325,000 | +45.8% | 1,332,815 | +90.5% | 1.48% | +15.2% |
| SRPT | Buy | Sarepta Therapeutics Inccall | $18,673,000 | +73.9% | 979,200 | +78.0% | 1.30% | +37.5% |
| STJ | New | ST JUDE MEDICAL | $18,174,000 | – | 233,000 | +100.0% | 1.26% | – |
| DBVT | Buy | DBV TECHNOLOGIES S Asponsored adr | $17,833,000 | +31.5% | 546,696 | +31.2% | 1.24% | +3.9% |
| QTNT | Buy | QUOTIENT LTD | $17,430,000 | -8.9% | 2,249,067 | +2.7% | 1.21% | -28.0% |
| EVH | Buy | EVOLENT HEALTH INCcl a | $16,763,000 | +156.5% | 873,064 | +41.1% | 1.16% | +102.8% |
| EGRX | Buy | EAGLE PHARMACEUTICALS INC | $11,637,000 | +53.5% | 300,000 | +60.2% | 0.81% | +21.4% |
| ALDX | Buy | ALDEYRA | $11,041,000 | +112.4% | 1,940,458 | +56.4% | 0.76% | +67.8% |
| WVE | Buy | WAVE LIFE SCIENCES LTD | $10,812,000 | +342.6% | 522,595 | +196.9% | 0.75% | +250.5% |
| CSU | Buy | CAPITAL SR LIVING CORP | $10,357,000 | +2.7% | 586,136 | +7.6% | 0.72% | -18.9% |
| HEDJ | New | WISDOMTREE EUROPE HEDGED EQUput | $10,106,000 | – | 200,000 | +100.0% | 0.70% | – |
| Buy | ALDER BIOPHARMACEUTICALS INC | $9,988,000 | +8.8% | 400,000 | +6.7% | 0.69% | -14.1% | |
| DXCM | Buy | DEXCOM INC | $9,930,000 | +452.3% | 125,174 | +372.8% | 0.69% | +335.4% |
| CRBP | Buy | CORBUS PHARMACEUTICALS HLDGS | $9,568,000 | +323.0% | 3,200,000 | +156.0% | 0.66% | +234.8% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $9,404,000 | +28.8% | 464,404 | +14.8% | 0.65% | +1.9% |
| AGTC | Buy | APPLIED GENETIC TECHNOL CORP | $9,309,000 | +2.4% | 658,851 | +1.3% | 0.64% | -19.2% |
| RGNX | Buy | REGENXBIO INC | $8,793,000 | -1.4% | 1,099,213 | +33.2% | 0.61% | -22.0% |
| CDTX | Buy | CIDARA THERAPEUTICS INC | $8,174,000 | -13.4% | 792,857 | +6.7% | 0.57% | -31.4% |
| AKBA | Buy | AKEBIA THERAPEUTICS INC | $6,684,000 | -14.2% | 893,600 | +3.3% | 0.46% | -32.3% |
| SELB | New | SELECTA BIOSCIENCES INC | $6,296,000 | – | 450,000 | +100.0% | 0.44% | – |
| FWP | Buy | FORWARD PHARMA A/Ssponsored adr | $5,658,000 | +78.7% | 311,400 | +67.1% | 0.39% | +41.0% |
| New | ACADIA PHARMACEUTICALS INC | $5,364,000 | – | 165,240 | +100.0% | 0.37% | – | |
| SUPN | Buy | SUPERNUS PHARMACEUTICALS INC | $5,093,000 | +67.0% | 250,000 | +25.0% | 0.35% | +31.7% |
| FOMX | New | FOAMIX PHARMACEUTICALS LTD | $5,048,000 | – | 795,000 | +100.0% | 0.35% | – |
| CLLS | Buy | CELLECTIS S Asponsored ads | $4,879,000 | +5850.0% | 183,507 | +6025.1% | 0.34% | +4728.6% |
| NEOS | Buy | NEOS THERAPEUTICS INC | $4,611,000 | +327.3% | 626,876 | +526.9% | 0.32% | +236.8% |
| ONS | New | ONCOBIOLOGICS INC | $4,463,000 | – | 1,312,763 | +100.0% | 0.31% | – |
| CLSD | New | CLEARSIDE BIOMEDICAL INC | $4,450,000 | – | 634,808 | +100.0% | 0.31% | – |
| TSRO | New | TESARO INCput | $4,203,000 | – | 50,000 | +100.0% | 0.29% | – |
| AGRX | Buy | AGILE THERAPEUTICS INC | $3,914,000 | +260.1% | 514,288 | +193.9% | 0.27% | +185.3% |
| TKAI | Buy | TOKAI PHARMACEUTICALS INC | $3,642,000 | +33.7% | 661,041 | +36.2% | 0.25% | +5.4% |
| CASC | New | Cascadian Therapeutics Inc | $3,220,000 | – | 3,414,121 | +100.0% | 0.22% | – |
| AVEO | New | AVEO PHARMACEUTICALS INC | $2,987,000 | – | 3,108,808 | +100.0% | 0.21% | – |
| INNL | New | INNOCOLL HLDGS PLC | $2,808,000 | – | 560,000 | +100.0% | 0.20% | – |
| CEMP | Buy | CEMPRA INC | $2,803,000 | +6.7% | 170,000 | +13.3% | 0.19% | -16.0% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $2,553,000 | +77.5% | 432,800 | +110.3% | 0.18% | +40.5% |
| New | ADMA BIOLOGICS INC | $2,371,000 | – | 398,394 | +100.0% | 0.16% | – | |
| IONS | New | Ionis Pharmaceuticals Ord Shsput | $2,329,000 | – | 100,000 | +100.0% | 0.16% | – |
| PGNX | New | PROGENICS PHARMACEUTICALSput | $2,110,000 | – | 500,000 | +100.0% | 0.15% | – |
| RLYP | New | RELYPSA INCput | $1,850,000 | – | 100,000 | +100.0% | 0.13% | – |
| AFMD | New | AFFIMED N V | $1,821,000 | – | 734,301 | +100.0% | 0.13% | – |
| MDGN | New | MEDGENICS INC | $1,665,000 | – | 300,000 | +100.0% | 0.12% | – |
| New | ABIOMED INC | $1,607,000 | – | 14,700 | +100.0% | 0.11% | – | |
| GMED | New | GLOBUS MED INCcl a | $1,192,000 | – | 50,000 | +100.0% | 0.08% | – |
| LPCN | New | LIPOCINE INCcall | $912,000 | – | 300,000 | +100.0% | 0.06% | – |
| LPCN | New | LIPOCINE INCput | $865,000 | – | 284,400 | +100.0% | 0.06% | – |
| PZRXQ | New | PHASERX INC | $852,000 | – | 200,000 | +100.0% | 0.06% | – |
| LXRX | New | Lexicon Pharmaceuticals Inc | $718,000 | – | 50,000 | +100.0% | 0.05% | – |
| LCI | New | LANNET INC | $634,000 | – | 26,670 | +100.0% | 0.04% | – |
| AET | New | AETNA INC NEW | $544,000 | – | 4,454 | +100.0% | 0.04% | – |
| New | AMN HEALTHCARE SERVICES INC | $537,000 | – | 13,445 | +100.0% | 0.04% | – | |
| WOOF | New | VCA INC | $537,000 | – | 7,940 | +100.0% | 0.04% | – |
| AGLE | New | AEGLEA BIOTHERAPEUTICS INC | $515,000 | – | 105,893 | +100.0% | 0.04% | – |
| ABC | New | AMERISOURCEBERGEN CORP | $516,000 | – | 6,500 | +100.0% | 0.04% | – |
| LH | New | LABORATORY CORP AMER HLDGS | $520,000 | – | 3,990 | +100.0% | 0.04% | – |
| CAH | Buy | CARDINAL HEALTH INC | $499,000 | +2.5% | 6,398 | +7.6% | 0.04% | -18.6% |
| KND | New | KINDRED HEALTHCARE INC | $478,000 | – | 42,301 | +100.0% | 0.03% | – |
| MOH | Buy | MOLINA HEALTHCARE INC | $459,000 | -11.6% | 9,200 | +14.3% | 0.03% | -30.4% |
| SCMP | Buy | SUCAMPO PHARMACEUTICALS INCcl a | $451,000 | +5537.5% | 41,096 | +5314.5% | 0.03% | +3000.0% |
| PAHC | New | PHIBRO ANIMAL HEALTH CORP | $453,000 | – | 24,300 | +100.0% | 0.03% | – |
| THC | New | TENET HEALTHCARE CORP | $448,000 | – | 16,200 | +100.0% | 0.03% | – |
| OPHT | New | OPHTHOTECH CORP | $416,000 | – | 8,145 | +100.0% | 0.03% | – |
| ENZ | New | ENZO BIOCHEM INC | $401,000 | – | 67,113 | +100.0% | 0.03% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $312,000 | – | 71,124 | +100.0% | 0.02% | – |
| NTLA | New | INTELLIA THERAPEUTICS INC | $320,000 | – | 15,000 | +100.0% | 0.02% | – |
| NVAX | New | NOVAVAX INC | $233,000 | – | 32,000 | +100.0% | 0.02% | – |
| MYL | New | MYLAN N V | $216,000 | – | 5,000 | +100.0% | 0.02% | – |
| ONSIW | New | ONCOBIOLOGICS INC*w exp 02/18/201 | $212,000 | – | 462,500 | +100.0% | 0.02% | – |
| ONSIZ | New | ONCOBIOLOGICS INC*w exp 05/18/201 | $202,000 | – | 462,500 | +100.0% | 0.01% | – |
| New | PERNIX THERAPEUTICS HLDGS INdbcv 4.250% 4/0 | $200,000 | – | 1,000,000 | +100.0% | 0.01% | – | |
| New | ABBOTT LABS | $120,000 | – | 3,040 | +100.0% | 0.01% | – | |
| PPHM | Buy | PEREGRINE PHARMACEUTICALS IN | $81,000 | +710.0% | 224,332 | +822.0% | 0.01% | +500.0% |
| DPLO | New | DIPLOMAT PHARMACY INC | $76,000 | – | 2,175 | +100.0% | 0.01% | – |
| IMGN | New | IMMUNOGEN INC | $79,000 | – | 25,745 | +100.0% | 0.01% | – |
| AIMT | New | AIMMUNE THERAPEUTICS INC | $70,000 | – | 6,448 | +100.0% | 0.01% | – |
| ABBV | New | ABBVIE INC | $77,000 | – | 1,250 | +100.0% | 0.01% | – |
| CORT | New | CORCEPT THERAPEUTICS INC | $60,000 | – | 11,000 | +100.0% | 0.00% | – |
| New | ATARA BIOTHERAPEUTICS INC | $56,000 | – | 2,500 | +100.0% | 0.00% | – | |
| JUNO | New | JUNO THERAPEUTICS INC | $43,000 | – | 1,113 | +100.0% | 0.00% | – |
| MCRB | New | SERES THERAPEUTICS INC | $45,000 | – | 1,540 | +100.0% | 0.00% | – |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $36,000 | – | 2,499 | +100.0% | 0.00% | – |
| BTX | New | BIOTIME INC | $36,000 | – | 13,740 | +100.0% | 0.00% | – |
| New | SEVION THERAPEUTICS | $12,000 | – | 59,220 | +100.0% | 0.00% | – | |
| GKOS | New | GLAUKOS CORP | $9,000 | – | 300 | +100.0% | 0.00% | – |
| New | AVINGER INC | $13,000 | – | 1,062 | +100.0% | 0.00% | – | |
| NPCUF | New | ALLON THERAPEUTICS | $0 | – | 751,124 | +100.0% | 0.00% | – |
| ZIOP | New | ZIOPHARM ONCOLOGY INC | $5,000 | – | 1,000 | +100.0% | 0.00% | – |
| TNGNQ | New | TENGION INC | $1,000 | – | 1,826,399 | +100.0% | 0.00% | – |
| VYGR | New | VOYAGER THERAPEUTICS INC | $7,000 | – | 650 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-11
About Perceptive Advisors
Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.
The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.
Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES SHARES | 42 | Q3 2023 | 15.7% |
| AMICUS THERAPEUTICS SHARES | 39 | Q3 2023 | 14.0% |
| ALDEYRA THERAPEUTICS SHARES | 35 | Q3 2023 | 3.3% |
| QUOTIENT TECHNOLOGY INC | 34 | Q3 2022 | 2.7% |
| GLOBAL BLOOD THERAPEUTICS SHARES | 29 | Q3 2022 | 9.3% |
| ADMA BIOLOGICS SHARES | 29 | Q3 2023 | 1.4% |
| RETROPHIN SHARES | 28 | Q3 2020 | 5.5% |
| DBV TECHNOLOGIES SA-SPON ADR | 28 | Q3 2021 | 1.8% |
| VBI VACCINES SHARES | 27 | Q1 2023 | 2.8% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
View Perceptive Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHEMBIO DIAGNOSTICS, INC.Sold out | May 04, 2023 | 0 | 0.0% |
| VBI Vaccines Inc/BC | April 07, 2023 | 43,509,553 | 16.7% |
| Landos Biopharma, Inc. | March 30, 2023 | 14,869,915 | 47.7% |
| REATA PHARMACEUTICALS INC | March 07, 2023 | 2,083,799 | 6.5% |
| AGILE THERAPEUTICS INCSold out | February 14, 2023 | 0 | 0.0% |
| ALBIREO PHARMA, INC. | February 14, 2023 | 1,757,160 | 8.5% |
| BELLUS Health Inc. | February 14, 2023 | 8,891,027 | 7.1% |
| CinCor Pharma, Inc. | February 14, 2023 | 2,576,325 | 5.9% |
| Coherus BioSciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CONCERT PHARMACEUTICALS, INC. | February 14, 2023 | 1,800,000 | 3.6% |
View Perceptive Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-05-01 |
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-04-17 |
| 4 | 2024-04-15 |
| SC 13G/A | 2024-04-15 |
| SC 13G | 2024-04-15 |
| SC 13D/A | 2024-04-10 |
| 4 | 2024-04-08 |
| 4 | 2024-04-03 |
| SC 13D/A | 2024-04-03 |
View Perceptive Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.